Risks of Study Abroad Sample Clauses

Risks of Study Abroad. I understand that there are inherent dangers associated with study abroad. These risks include, but are not limited to: accidents, injury, illness, disease, death, unusual living conditions, different safety and accommodation standards, natural and weather disasters, dangerous insects and animals, criminal behavior, civil strife, terrorism, and any other harm, injury, illness or damage that can occur. I understand that Evergreen, its instructors, or its agents do not serve as guardians or insurers of my absolute safety. I have made my own assessment of these inherent dangers by reviewing the various resources listed below, and I am willing to accept these risks. initials International Organization for Medical Assistance to Travelers: Join for free. xxxxx://xxx.xxxxx.xxx/ U.S. Centers for Disease Control: xxxxx://xxx.xxx.xxx/ World Health Organization: xxxx://xxx.xxx.xxx/home U.S. State Department: Country Information: xxxxx://xxxxxx.xxxxx.xxx/content/travel/en/international- travel/International-Travel-Country-Information-Pages.html U.S. State Department: Your Health Abroad: xxxxx://xxxxxx.xxxxx.xxx/content/travel/en/international- travel/before-you-go/your-health-abroad.html
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Risks of Study Abroad. A. I understand that participation in the Program involves risks not found in study at the College. These include risks involved in traveling to and within, and returning from, one or more foreign countries; foreign political, legal, social and economic conditions; different standards of design, safety and maintenance of buildings, public places and conveyances; local medical and weather conditions; and other matters described in the attached U.S. Department of State Country Specific Information (and Travel Warnings and/or Travel Alerts, if any) that I have received, reviewed, and initialed, and which are incorporated by reference in this Waiver and Release Agreement (“Release”). B. Knowing these risks, and in consideration of being permitted to participate in the Program, I agree, on behalf of my family, heirs and personal representative(s), to assume all the risks and responsibilities surrounding my participation in the Program. I understand that, although the University has made every reasonable effort to assure my safety while participating in the Program, there are unavoidable risks in travel overseas, and I hereby release and promise not to xxx the City of New York, the State of New York, the College, the University, and the officers, employees or agents of any and all of them, for any damages or injury (including death) caused by, deriving from, or associated with my participation in the Program, except for such damages or injury as may be caused by the gross negligence or willful misconduct of the officers, employees or agents of any of them.
Sample 1
Risks of Study Abroad. I am aware of and understand the risks and dangers of travel to, in, and around the Program country, including but not limited to the dangers to my own health and personal safety posed by the use of public transportation, and by civil unrest, political instability, terrorism, crime, violence, and disease. Prior to departure I will review the U.S. Consular Information and the Centers for Disease Control information applicable to travel to, in and around the Program country. By my participation in this Program, I assume, knowingly and voluntarily, each of these risks and all of the other risks that could arise out of or occur during my travel to, from, in, or around the Program country.
Sample 1Sample 2
Risks of Study Abroad. I understand that there are inherent dangers associated with participating in this program, contract, or consortium away from campus. These risks include, but are not limited to: accidents, injury, illness, disease, unusual living conditions, different safety and accommodation standards, natural and weather disasters, dangerous insects and animals, criminal behavior, civil strife, terrorism, and any other harm, injury, illness or damage which may befall me. I understand that the Evergreen State College (Evergreen), its instructors, or its agents do not serve as guardians or insurers of my absolute safety. I have made my own assessment of these inherent dangers by reviewing the various study abroad materials, U.S. State Department documents, and Center for Disease Control documents listed below, and I am willing to accept these risks. _____ initials U.S. State Department Country-Specific Information Pages xxxxx://xxxxxx.xxxxx.xxx/content/passports/en/country.html I have read and understand the contents of the Country Specific Information Sheets for the countries I will be visiting. _____ initials I have read and understand the contents, recommendations, and requirements of the CDC Traveler’s Health Pages for my destination countries. _____ initials I have read and understand the information contained in the Evergreen pre-departure materials provided to me. _____ initials
Sample 1
Risks of Study Abroad. I understand that there are inherent dangers associated with study abroad. These risks include, but are not limited to: accidents, injury, illness, disease, COVID-19, death, unusual living conditions, different safety and accommodation standards, natural and weather disasters, dangerous insects and animals, criminal behavior, civil strife, terrorism, and any other harm, injury, illness or damage that can occur. I understand that Evergreen, its instructors, or its agents do not serve as guardians or insurers of my absolute safety. I have made my own assessment of these inherent dangers by reviewing the various resources listed below, and I am willing to accept these risks. initials
Sample 1
Risks of Study Abroad. I understand that participation in the Program involves risks not found in study at KCC. These risks include: traveling to and within, and returning from, one or more foreign countries; foreign political, legal, social, and economic conditions; different standards of design, safety, and maintenance of buildings, public places, and conveyances; and other matters which may be described in brochures and other written information concerning this Program, which I have received and reviewed. I have made my own investigation and am willing to accept these risks.
Sample 1
Risks of Study Abroad. A. I understand that participation in a study program involves risks not found in study at the College. These may include but are not limited to risks involved in traveling to and within and returning from, one or more foreign countries; foreign political, legal, social and economic conditions; different standards of design, safety and maintenance of buildings, public places and conveyances; local medical and weather conditions and other matters described in the attached U.S. Department of State Consular Information Sheet and Travel Warning (if any) which I have received, reviewed and initialed, and which are incorporated by reference in this Waiver and Release Agreement. B. Knowing these risks I agree, on behalf of my family, heirs and personal representative(s), to assume all the risks and responsibilities surrounding my participation in the program. I hereby release and promise not to xxx Mercy College, and the officers, employees or faculty, or any of their agents, for any damages or injury (including death) caused by, deriving from, or associated with my participation in the program.
Sample 1
AutoNDA by SimpleDocs
Risks of Study Abroad. I understand that participation in my program abroad involves risks not found on my home campus. These risks include without limitation traveling to and within, and returning from, WIA and other international locations; foreign political, legal, social and economic conditions; different standards of design, safety and maintenance of buildings, public places including roads and highways, and public or private transportation; local medical services or facilities; and weather conditions. The country(ies) in which my program may operate may have health and safety standards substantially different from those in the United States. I recognize that I may be subjected to potential personal or financial loss, illnesses, injuries and even death arising from participating in an activity or contact with physical surroundings; insects or animals; biological hazards such as mold, bacteria, viruses, infectious materials, bloodborne pathogens or other hazards; equipment; food, drink or shelter; or other persons. I acknowledge that this list is not inclusive of all possible risks associated with the program and certify that I have made my own investigation of these risks, understand these risks and assume them knowingly and willingly.
Sample 1
Risks of Study Abroad. I understand that participation in the GCTS approved program specified above (the “Program”) involves risks not found in on-campus coursework. These include risks involved in traveling to and within, and returning from, one or more foreign countries; foreign political, legal, social, and economic conditions; local medical and weather conditions; different standards of design, safety and maintenance of buildings, public places and conveyances; and increased potential for theft of personal property (which is not covered by the Seminary’s insurance).
Sample 1

Related to Risks of Study Abroad

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • The Study 1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Technical Feasibility of String While ICANN has encouraged and will continue to encourage universal acceptance of all top-­‐level domain strings across the Internet, certain top-­‐level domain strings may encounter difficulty in acceptance by ISPs and webhosters and/or validation by web applications. Registry Operator shall be responsible for ensuring to its satisfaction the technical feasibility of the TLD string prior to entering into this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!